Emerging human data suggest that GLP1 receptor agonists may improve central insulin sensitivity and brain glucose handling
Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS
However, Mathiesen et al
If food noise is loud, track hunger, cravings, protein, hydration, sleep quality, mood, energy, side effects, stress, and notes about what was happening that day
Scientific references TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial (NEJM, 2023) Retatrutide for people with type 2 diabetes a Phase 2 trial (The Lancet, 2023) LY3437943 (retatrutide), a triple GIP/GLP-1/glucagon agonist Phase 1b trial MHRA: avoid illegal online weight-loss medicines MHRA Drug Safety Update: GLP-1 / GIP agonists pancreatitis warnings NICE TA875: Semaglutide for overweight and obesity NICE TA1026: Tirzepatide for overweight and obesity Incretin-based drugs and gallbladder / biliary disease (The Lancet) Final word for UK research customers A retatrutide 40mg pen is a pre-filled, ready-to-use research peptide with 40mg in the tank roughly 240 clicks, enough for many small doses or a handful of big ones
Read the full story here: What GLP1 users need: Food, nutrition and CPG innovation Nestl signals strategic reset in a shifting market The last month marked a critical moment for Nestl, as its CEO Phillip Navratil outlined a broader strategic overhaul aimed at sharpening focus, restoring growth and responding to changing consumer demand
